![Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict](https://mv.ecuo.org/wp-content/uploads/sites/4/2018/02/lawsuit-judge-law-copyright-patent-infringement-270x189_c.jpg)
Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict
A federal judge in Delaware has overturned a jury’s verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.